Market News

Pharma company will provide fill and finish manufacturing capacity at its Barnard Castle facility as early as the beginning of May 2021

Some seaborne deliveries are being rerouted or switched to air transportation as efforts to re-float stricken Ever Given container vessel move into fourth day

Company will use extension of Schedule I licence to start development of psychedelics-based pipeline to treat mental health disorders

The company will triple its capacity and workforce at its North Carolina site to increase its global capabilities and reach

The CDMO's Zydis technology will help the Canadian biotech to develop fast-acting, shorter-duration formulations of its potential therapy for treatment-resistant psychiatric disorders

Despite COVID-related challenges and supply chain issues, the CDMO's $240 million new facility is on target to open next year

The move ensures the service provider has the capacity to meet the needs of an evolving clinical market

US-headquartered company Kindeva seals deal for an R&D facility at Loughborough’s life sciences hub

Regulators stress temporary halt is precautionary measure and that there is currently no evidence linking the shot to adverse events

Tremendous growth opportunities exist for auto-injectors as their value is increasingly being recognised across several therapy areas, experts have told a recent CPHI webinar, sponsored by Stevanato Group.

The purchase will allow the company to add nine new customers to its growing CDMO business and 27 manufacturing suites

The enhancements will include installing the lever-operated multi-dose inhaler device used in Hikma’s generic Advair product, which the FDA recently approved

During the next 12 months, demand for early-stage contract projects could quickly exceed supply

PsiVac has generated compelling efficacy data in killing a broad range of tumour cells, including head and neck, bladder, liver, pancreatic and ovarian

Funding from BARDA helps the company to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2 vaccines and medicines

The addition further strengthens WuXi's cell and gene therapy service offerings for global customers and will be Wuxi ATU's first facility in Europe

The company wins awards in all six categories — capabilities, compatibility, expertise, quality, reliability and service

This transaction complements Pharmaron’s recent acquisition of Absorption Systems in the US for building an integrated cell and gene therapy services platform

The company acquires a pDNA CDMO and launches pDNA development and manufacturing services at its Rockville, Maryland facility

The new site will be equipped to enable quick ramp-up of capacity for clinical and commercial cell therapy products

The CDMO will manufacture recently FDA-approved Lupkynis as a softgel dosage form at its St Petersburg, Florida, facility

The manufacturing agreement includes process development for scale-up and technology transfer with the goal of supplying Phase II and III clinical studies

API manufacturer says acquisition is next step of investment strategy to closely align API supply to customer needs in an unpredictable world

CDMO says increased customer demand for clinical API supply has outstripped its cGMP manufacturing capacity

The CDMO doubles its capacity to take on new development projects

The expanded and refined first-in-human services have been designed to meet the early-stage molecule development of small biopharma players

The company seeks to actively accelerate US manufacturing for medicines at risk of shortage, including those for COVID-19 pandemic response

The company's additional production capacities are scheduled to go into operation in May 2021

Firms plan to invest in capacity expansion at the CDMO’s manufacturing site in Dessau to boost European domestic vaccine supply

The CRO predicts investment communities will come to the rescue of small and medium companies looking to advance their candidates

The CMO has designed the new service to alleviate manufacturing challenges associated with positive controls and nucleic acid templates

The acquisition will expand the CDMO's capabilities and capacity to serve European markets

By Yifei Chen and Yasemin Bettina Karanis, IQVIA

By Yifei Chen and Yasemin Bettina Karanis, IQVIA

The CPO's new division will offer a holistic blister packaging development service, complete with QA and non-destructive leak testing, encompassing material selection, tooling design, and 3D prototyping

Joint venture between Recipharm and Medspray could provide significant advantages for patients and the environment, companies say

How are changes in new treatments and disease areas – as well as the current pandemic crisis - affecting demand for APIs?

European Commission pressures pharma firm over reduced shipments amid criticism for slow vaccine rollout across block

The CDMO gears up for rapid deployment of its clinical-to-commercial manufacturing operations for its seventh collaboration to help deliver COVID-19 treatments

The donation from Ineos will create a new institute to tackle the "silent pandemic"

The collaboration aims to accelerate the development and commercialization of groundbreaking cell-based regenerative cures

Expanded global capacity addresses growing demand for cell and gene therapy

AmpTec's differentiated PCR-based technology has shown to have advantages compared with other technologies for mRNA manufacturing

Manufacturing at Baxter's Halle/Westfalen, Germany facility will help increase commercial production and promote access in UK and European markets

The new facility will house up to 12 X 2000-L bioreactors and will be equipped to handle existing and new advances in manufacturing

The $40 million investment marks the company's third viral vector manufacturing site

Acquisition will extend the Chinese CDMO’s European footprint and will complement Leverkusen drug product site

CDMO will add two production suites for clinical and commercial supply and extend lab space to double analytical and process development capacity

Newly formed generics business identifies the first five impacted plants as it seeks to reduce costs by $1 billion by the end of 2024

The company will be responsible for the formulation, filling, and packaging of Ad26.COV2-S at its new €30 million injectable products plant in Barcelona

Two new facilities in Germany will provide clinical supply and cold chain services to support growing demand

Through the acquisition, Lilly will establish a gene therapy program via Prevail's gain clinical-stage and preclinical neuroscience assets

The expansion will enable the CDMO to widen the nature of inhaled drug development projects it can undertake for customers

Dutch CDMO will expand with two additional viral vector production lines to meet the increased demand

The CDMO will provide packaging, labeling and distribution services through its FastChain demand-led supply offering

The first-of-its-kind manufacturing service delivers tested sterile, non-GMP media designed for feasibility testing before scale-up, to support development of cell and gene therapies

Industry customers now have access to 24/7 real-time shipment visibility across the company's entire product portfolio

The company will invest in dedicated early-phase development and cGMP manufacturing to help customers rapidly advance challenging molecules

AZD1222 is 90% effective, cheap to produce and easy to store, distribute and administer

The CDMO is already making certain investments to enable technology transfer and scale-up to commence imminently.

The partnership will focus on commercializing eight biosimilar medicines in China for the domestic market

The agreement comes hot on the heels of FDA approval of Gavreto — Blueprint Medicines' new treatment for lung cancer

Data also show that mRNA-1273 remains stable at 2–8°, the temperature of a standard home or medical refrigerator, for 30 days.

The facility will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.

Europeans set to benefit from the EC's authorization of COVID-19 candidate vaccine supply agreement, securing up to 405 million doses of CVnCoV

Resyca BV will provide a "unique offering" to the market — environmentally friendly, softmist spray nozzle technology for pharmaceutical applications.

The specialist CDMO's $150 million 3-year investment plan will provide a complete suite of virotherapy services to support drug developers and their most "revolutionary" products.

This phase sees the CDMO start work on installing two 2,000-L single-use bioreactor trains in its mammalian cGMP facility.

Results from a Phase III clinical study found Pfizer and BioNTech's mRNA-based vaccine candidate, BNT162b2, is more than 90% effective in preventing COVID-19 in participants without evidence of prior SARS-CoV-2 infection, the companies announced Monday...

The expansion will bolster the CDMO's offering by ensuring it can fulfil the forecasted increase in demand for respiratory devices.

Altimmune adds Lonza as a manufacturing partner for supply of AdCOVID, its single-dose intranasal vaccine candidate for COVID-19.

CMO growth, however, hampered by innovator approvals from mega-cap pharma.

In this interview with Pharmapack, Arnaud Steiner, R&D Packaging Manager at Virbac shares his thoughts on trending issues in the packaging market such as patient centricity and eco-design, the challenges of managing the development of new packaging and...

Company is the latest in a lengthening list of pharma companies recalling the diabetes medicine over unacceptable levels of NDMA

Device provides clinicians and trialists with comprehensive data on a patient's adherence pattern.

The expansion will entail building two new facilities - one in Germany, the other in Japan.

Initial stage of new facility planned for Ringaskiddy site to manufacture medicines for clinical trials.

The companies anticipate first results of Phase I/II in early December 2020, to support the initiation of a pivotal Phase III study before the end of the year.

Panel at CPHI Festival of Pharma discusses options for companies to ensure robust supply chains and reduce overseas supply dependency

The Russian Federation has become one of the first countries to apply to the WHO for prequalification of its vaccine, Sputnik V, against the novel coronavirus infection.

Company closes "key" plants in India, the US, Russia and Brazil as a precautionary measure.

The CRDMO will expand in vitro and in vivo biology services, DMPK and toxicology capabilities.

The expansion at eight global Lonza sites will increase manufacturing capacity by 30 billion capsules annually.

Allows companies to proactively monitor their serialized operations and gain actionable insights to avoid costly delays and ensure product availability.

The biopharma company collaborates with European and Canadian suppliers for large-scale ramp-up of opaganib manufacturing.

2021 will bring global pharma community back together, in person, to drive business growth.

The CDMO's Pathway TPUs are well-recognized as an effective option for many drug delivery systems.

The recipe for efficiency by Universal Pack

MPA Technical Devices Srl is an Italian company specializing in designing and manufacturing top quality and accurate dosing systems.

CycloLab Cyclodextrin Research and Development Ltd. is a private SME with the focus on cyclodextrin research and development for over 30 years. We are working in the fields of pharmaceutical, cosmetic and food industry, agrochemical, environmental and ...

New ‘blockchain ecosystem’ has potential to track, from vein-to-vein, advanced therapies.

Manufacturing facility upgrades have substantially increased the CDMO’s production capacity and energy efficiency.

The technology eliminates the processing and performance challenges associated with conventionally coated delayed-release softgels.

While there have been some huge advances in vaccine technology, more still needs to be done to counter the threat that infectious diseases pose, particularly to poorer countries.

The investment will support increased demand and help to secure new business at its Kaysersberg facility.

The strategic acquisition of Axpharma is part of the group’s aim to widen its expertise and global reach as the pandemic forces renewed focus on safety, quality and speed-to-market.

Excellence in Pharma recognised at virtual ceremony taking place at the CPHI Festival of Pharma.

Investment includes the installation two of automated top-loading cartoner with the flexibility to pack vials, syringes, pens/autoinjectors and multi-component kits.

The expansion increases the company's capacity and provides its clients with larger process crystallization development, up to 20-L scale.

Former FDA Commissioner lays out roadmap for building out excess capacity to deal with pandemic situations

The facility will enable the company to deliver Phase I to commercial manufacturing services for biologic projects.

The CPHI Festival of Pharma is well underway! Tune into this podcast in which Informa Markets Head of Pharma Content, Tara Dougal, and Pharma Editor, Gareth Carpenter review some of the highlights of the first few days as well as a preview of what's co...

The two suites, established with VMIC equipment and operated by Oxford Biomedica, will be operating at 1000-L scale.

Flexible support system simplifies and secures tubing paths for biopharmaceutical manufacturers.

BIA Separations will be Sartorius's center of excellence for purification of cell and gene therapeutics.

Scancell’s DNA vaccine could provide long-lasting immunity against COVID-19 by generating protection against this and new strains of coronavirus.

Inspection conducted remotely using video-conferencing and an online private document sharing platform.

Hugh Purity New England's solution can utilize other vendors' components and can be implemented directly into any process.

Up to 500 doses of vaccine to be placed on a single wafer-thin and stored for extended periods of time.

The new centre will allow the company to improve efficiencies and reduce overall manufacturing time.

Novel therapy developed by Australian biotech company, Ena Respiratory, shown to significantly reduce COVID-19 virus levels in the nose and throat.

Survey results reveal 84% of the industry is actively searching for new partners.

The companies will commercialize six new biosimilar candidates addressing multiple therapeutic areas.

Expanded CRO services to support biotechs and mid-sized pharma companies across trials in more than 40 countries.

The targeted removal of one particular bacterial species from the skin microbiome, while preserving the beneficial ones, represents a new way to treat atopic dermatitis.

Catalent to manufacture clinical batches of T-knife's platform process for TCR-based cell therapy at its site in Gosselies, Belgium, for European trials in 2021.

Clients set to benefit immediately through "higher yields" and "improved potent handling".

Novel, plasmid-free manufacturing system reduces the cost of goods and improves AAV quality to enable development of safer gene therapies.